Cost-savings to medicare from pre-medicare colorectal cancer screening
Background: Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Med...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/49924 |
| _version_ | 1848758351263956992 |
|---|---|
| author | Goede, S. Kuntz, K. Van Ballegooijen, M. Knudsen, A. Lansdorp_Vogelaar, Iris Tangka, F. Howard, D. Chin, J. Zauber, A. Seeff, L. |
| author_facet | Goede, S. Kuntz, K. Van Ballegooijen, M. Knudsen, A. Lansdorp_Vogelaar, Iris Tangka, F. Howard, D. Chin, J. Zauber, A. Seeff, L. |
| author_sort | Goede, S. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Background: Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Medicare populations (65+ y). Methods: We used 2 independently developed microsimulation models [Microsimulation Screening Analysis Colon (MISCAN) and Simulation Model of CRC (SimCRC)] to project CRC screening and treatment costs under 2 scenarios, starting in 2010: "current trends" (60% of the population up-to-date with screening recommendations) and "enhanced participation" (70% up-to-date). The population was scaled to the projected US population for each year between 2010 and 2060. Costs per year were derived by age group (50-64 and 65+ y). Results: By 2060, the discounted cumulative total costs in the pre-Medicare population were $35.7 and $28.1 billion higher with enhanced screening participation, than in the current trends scenario ($252.1 billion with MISCAN and $239.5 billion with SimCRC, respectively). Because of CRC treatment savings with enhanced participation, cumulative costs in the Medicare population were $18.3 and $32.7 billion lower (current trends: $423.5 billion with MISCAN and $372.8 billion with SimCRC). Over the 50-year time horizon an estimated 60% (MISCAN) and 89% (SimCRC) of the increased screening costs could be offset by savings in Medicare CRC treatment costs. Conclusion: Increased CRC screening participation in the pre-Medicare population could reduce CRC incidence and mortality, whereas the additional screening costs can be largely offset by long-term Medicare treatment savings. |
| first_indexed | 2025-11-14T09:42:36Z |
| format | Journal Article |
| id | curtin-20.500.11937-49924 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:42:36Z |
| publishDate | 2015 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-499242018-03-29T09:07:08Z Cost-savings to medicare from pre-medicare colorectal cancer screening Goede, S. Kuntz, K. Van Ballegooijen, M. Knudsen, A. Lansdorp_Vogelaar, Iris Tangka, F. Howard, D. Chin, J. Zauber, A. Seeff, L. Background: Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Medicare populations (65+ y). Methods: We used 2 independently developed microsimulation models [Microsimulation Screening Analysis Colon (MISCAN) and Simulation Model of CRC (SimCRC)] to project CRC screening and treatment costs under 2 scenarios, starting in 2010: "current trends" (60% of the population up-to-date with screening recommendations) and "enhanced participation" (70% up-to-date). The population was scaled to the projected US population for each year between 2010 and 2060. Costs per year were derived by age group (50-64 and 65+ y). Results: By 2060, the discounted cumulative total costs in the pre-Medicare population were $35.7 and $28.1 billion higher with enhanced screening participation, than in the current trends scenario ($252.1 billion with MISCAN and $239.5 billion with SimCRC, respectively). Because of CRC treatment savings with enhanced participation, cumulative costs in the Medicare population were $18.3 and $32.7 billion lower (current trends: $423.5 billion with MISCAN and $372.8 billion with SimCRC). Over the 50-year time horizon an estimated 60% (MISCAN) and 89% (SimCRC) of the increased screening costs could be offset by savings in Medicare CRC treatment costs. Conclusion: Increased CRC screening participation in the pre-Medicare population could reduce CRC incidence and mortality, whereas the additional screening costs can be largely offset by long-term Medicare treatment savings. 2015 Journal Article http://hdl.handle.net/20.500.11937/49924 10.1097/MLR.0000000000000380 restricted |
| spellingShingle | Goede, S. Kuntz, K. Van Ballegooijen, M. Knudsen, A. Lansdorp_Vogelaar, Iris Tangka, F. Howard, D. Chin, J. Zauber, A. Seeff, L. Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title | Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title_full | Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title_fullStr | Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title_full_unstemmed | Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title_short | Cost-savings to medicare from pre-medicare colorectal cancer screening |
| title_sort | cost-savings to medicare from pre-medicare colorectal cancer screening |
| url | http://hdl.handle.net/20.500.11937/49924 |